Autonomous screening
AEYE Health
Autonomously screens retinal images for more-than-mild diabetic retinopathy using compatible cameras.
Designed for
Healthcare provider
Care setting
Primary care and mobile screening
Specialty
Ophthalmology, Primary care
Our assessment
AEYE-DS has prospective FDA-reviewed evidence supporting autonomous detection of more-than-mild diabetic retinopathy with a defined camera and workflow. Broader confidence depends on real-world imageability, referral completion, hardware configuration, equity, and post-update performance.
Based on public sources. RIR did not independently test this product. This is not an endorsement or recommendation.
What the evidence supports
Reviewed sources establish an authorized autonomous diabetic retinopathy screening product for defined cameras and patients.
What remains uncertain
Independent local evidence on imageability, subgroup performance, referral completion, and long-term outcomes remains needed.
How it was studied
The FDA 510(k) summary states that AEYE-DS version 5.00 was tested in a prospective, multicenter, single-arm, blinded pivotal study. Novice operators captured retinal images, and patient-level output was compared with the study reference assessment.
Product facts
Sources reviewed
3 public sources represented in this evidence profile.
Evidence source base
FDA-reviewed developer-sponsored pivotal evidence and official product materials.
Important limitation
Pivotal diagnostic performance does not establish referral completion, performance with every camera or operator, equity, long-term outcomes, or continued performance after version changes.
Questions to ask